Novartis Oncology Pipeline Has Lucky 13 Clinical Candidates
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Novartis Institute for Biomedical Research's six-year-old mechanism-based research model is cranking out targeted cancer therapeutics, with three new molecules headed for the clinic by the end of 2008
You may also be interested in...
Tekturna Will Track Diovan’s Steady Growth To Blockbuster Status - Novartis
Novartis is hoping sales of its new blood pressure drug Tekturna will climb steadily as morbidity and mortality data amass, eventually leading it to blockbuster status on the same trajectory as top-selling Diovan
Pfizer's Increasingly Specialist Focus
Pfizer's brand-new oncology business unit appears to be the linchpin in its transformation from primary care behemoth to specialty powerhouse. The Big Pharma also followed this up with the announcement that it was cutting early-stage R&D programs focused on obesity, bone health, and what has been its mainstay--cardiovascular disease. Together, these moves should be viewed as the most extreme example of the industry's flight from primary care medicine into the safer haven of specialty-focused pharmaceuticals,
Novartis Speeds RAD001 Filing Schedule After Presenting RECORD-1 At ASCO
CHICAGO - With data in hand showing RAD001 (everolimus) doubled progression-free survival in metastatic kidney cancer, Novartis is accelerating its submission schedule and plans to file for the indication by July for a possible 2009 launch of its mTOR inhibitor for oncology